241 related articles for article (PubMed ID: 11196262)
1. Disease outcome may be predicted by molecular detection of minimal residual disease in bone marrow in advanced neuroblastoma: a pilot study.
Fukuda M; Miyajima Y; Miyashita Y; Horibe K
J Pediatr Hematol Oncol; 2001 Jan; 23(1):10-3. PubMed ID: 11196262
[TBL] [Abstract][Full Text] [Related]
2. Outcome prediction by molecular detection of minimal residual disease in bone marrow for advanced neuroblastoma.
Horibe K; Fukuda M; Miyajima Y; Matsumoto K; Kondo M; Inaba J; Miyashita Y
Med Pediatr Oncol; 2001 Jan; 36(1):203-4. PubMed ID: 11464885
[TBL] [Abstract][Full Text] [Related]
3. Detection of neuroblastoma cells in bone marrow and peripheral blood at diagnosis by the reverse transcriptase-polymerase chain reaction for tyrosine hydroxylase mRNA.
Miyajima Y; Kato K; Numata S; Kudo K; Horibe K
Cancer; 1995 Jun; 75(11):2757-61. PubMed ID: 7743482
[TBL] [Abstract][Full Text] [Related]
4. Impact of minimal residual disease detection prior to autologous stem cell transplantation for post-transplant outcome in high risk neuroblastoma.
Bochennek K; Esser R; Lehrnbecher T; Glienke W; Wehner S; Erben S; Soerensen J; Schwabe D; Bader P; Klingebiel T; Koehl U
Klin Padiatr; 2012 Apr; 224(3):139-42. PubMed ID: 22377741
[TBL] [Abstract][Full Text] [Related]
5. Minimal residual disease at the time of peripheral blood stem cell harvest in patients with advanced neuroblastoma.
Burchill SA; Kinsey SE; Picton S; Roberts P; Pinkerton CR; Selby P; Lewis IJ
Med Pediatr Oncol; 2001 Jan; 36(1):213-9. PubMed ID: 11464888
[TBL] [Abstract][Full Text] [Related]
6. Sequential detection of tumor cells in the peripheral blood and bone marrow of patients with stage IV neuroblastoma by the reverse transcription-polymerase chain reaction for tyrosine hydroxylase mRNA.
Miyajima Y; Horibe K; Fukuda M; Matsumoto K; Numata S; Mori H; Kato K
Cancer; 1996 Mar; 77(6):1214-9. PubMed ID: 8635146
[TBL] [Abstract][Full Text] [Related]
7. Comparison of two methods for evaluating bone marrow metastasis of neuroblastoma: Reverse transcription-polymerase chain reaction for tyrosine hydroxylase and magnetic resonance imaging.
Takemoto C; Nishiuchi R; Endo C; Oda M; Seino Y
Pediatr Int; 2004 Aug; 46(4):387-93. PubMed ID: 15310300
[TBL] [Abstract][Full Text] [Related]
8. Minimal residual disease is a prognostic marker for neuroblastoma with bone marrow infiltration.
Cai JY; Pan C; Tang YJ; Chen J; Ye QD; Zhou M; Xue H; Tang JY
Am J Clin Oncol; 2012 Jun; 35(3):275-8. PubMed ID: 21537148
[TBL] [Abstract][Full Text] [Related]
9. TH and DCX mRNAs in peripheral blood and bone marrow predict outcome in metastatic neuroblastoma patients.
Yáñez Y; Hervás D; Grau E; Oltra S; Pérez G; Palanca S; Bermúdez M; Márquez C; Cañete A; Castel V
J Cancer Res Clin Oncol; 2016 Mar; 142(3):573-80. PubMed ID: 26498952
[TBL] [Abstract][Full Text] [Related]
10. Prospective investigation of applicability and the prognostic significance of bone marrow involvement in patients with neuroblastoma detected by quantitative reverse transcription PCR.
Druy AE; Shorikov EV; Tsaur GA; Popov AM; Zaychikov AN; Tuponogov SN; Saveliev LI; Tytgat GAM; Fechina LG
Pediatr Blood Cancer; 2018 Nov; 65(11):e27354. PubMed ID: 30007008
[TBL] [Abstract][Full Text] [Related]
11. Prognostic influence of minimal residual disease detected by flow cytometry and peripheral blood stem cell transplantation by CD34+ selection in childhood advanced neuroblastoma.
Cai JY; Tang YJ; Jiang LM; Pan C; Chen J; Tang JY
Pediatr Blood Cancer; 2007 Dec; 49(7):952-7. PubMed ID: 17514736
[TBL] [Abstract][Full Text] [Related]
12. Detection of micrometastasis of neuroblastoma to bone marrow and tumor dissemination to hematopoietic autografts using flow cytometry and reverse transcriptase-polymerase chain reaction.
Tsang KS; Li CK; Tsoi WC; Leung Y; Shing MM; Chik KW; Lee V; Ng MH; Yuen P
Cancer; 2003 Jun; 97(11):2887-97. PubMed ID: 12767104
[TBL] [Abstract][Full Text] [Related]
13. Clinical application of minimal residual neuroblastoma cell detection by reverse transcriptase-polymerase chain reaction.
Kuroda T; Saeki M; Nakano M; Mizutani S
J Pediatr Surg; 1997 Jan; 32(1):69-72. PubMed ID: 9021573
[TBL] [Abstract][Full Text] [Related]
14. Real-time RT-PCR of tyrosine hydroxylase to detect bone marrow involvement in advanced neuroblastoma.
Pession A; Libri V; Sartini R; Conforti R; Magrini E; Bernardi L; Fronza R; Olivotto E; Prete A; Tonelli R; Paolucci G
Oncol Rep; 2003; 10(2):357-62. PubMed ID: 12579272
[TBL] [Abstract][Full Text] [Related]
15. Clinical implications of minimal disease in the bone marrow and peripheral blood in neuroblastoma.
Shono K; Tajiri T; Fujii Y; Suita S
J Pediatr Surg; 2000 Oct; 35(10):1415-20. PubMed ID: 11051140
[TBL] [Abstract][Full Text] [Related]
16. Neuroblastoma: treatment outcome after incomplete resection of primary tumors.
Moon SB; Park KW; Jung SE; Youn WJ
Pediatr Surg Int; 2009 Sep; 25(9):789-93. PubMed ID: 19629500
[TBL] [Abstract][Full Text] [Related]
17. Multivariate analysis of risk factors in stage 4 neuroblastoma patients over the age of one year treated with megatherapy and stem-cell transplantation: a report from the European Bone Marrow Transplantation Solid Tumor Registry.
Ladenstein R; Philip T; Lasset C; Hartmann O; Garaventa A; Pinkerton R; Michon J; Pritchard J; Klingebiel T; Kremens B; Pearson A; Coze C; Paolucci P; Frappaz D; Gadner H; Chauvin F
J Clin Oncol; 1998 Mar; 16(3):953-65. PubMed ID: 9508178
[TBL] [Abstract][Full Text] [Related]
18. mRNAs of tyrosine hydroxylase and dopa decarboxylase but not of GD2 synthase are specific for neuroblastoma minimal disease and predicts outcome for children with high-risk disease when measured at diagnosis.
Träger C; Vernby A; Kullman A; Ora I; Kogner P; Kågedal B
Int J Cancer; 2008 Dec; 123(12):2849-55. PubMed ID: 18814238
[TBL] [Abstract][Full Text] [Related]
19. Results of induction chemotherapy in children older than 18 months with stage-4 neuroblastoma treated with an adaptive-to-response modified N7 protocol (mN7).
Mora J; Cruz O; Lavarino C; Rios J; Vancells M; Parareda A; Salvador H; Suñol M; Carrasco R; Guillen A; Mañé S; de Torres C
Clin Transl Oncol; 2015 Jul; 17(7):521-9. PubMed ID: 25596034
[TBL] [Abstract][Full Text] [Related]
20. PHOX2B is a novel and specific marker for minimal residual disease testing in neuroblastoma.
Stutterheim J; Gerritsen A; Zappeij-Kannegieter L; Kleijn I; Dee R; Hooft L; van Noesel MM; Bierings M; Berthold F; Versteeg R; Caron HN; van der Schoot CE; Tytgat GA
J Clin Oncol; 2008 Nov; 26(33):5443-9. PubMed ID: 18838715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
